Open AccessSafety and immunological effectiveness of the domestic combined trivaccine for the prevention of measles, rubella and mumps Vaktrivir<sup>®</sup> in children 12 months and 6 years of age (results of a simple blind multicenter comparative randomized clinical trial)
Author(s) -
И. В. Фельдблюм,
В. В. Романенко,
К. А. Субботина,
M. G. Menshikova,
И. А. Окунева,
А. Ю. Мусихина,
Т. Э. Снитковская,
Nina I. Markovich,
Aleksey Ershov,
Д. М. Трофимов
Publication year - 2021
Publication title -
èpidemiologiâ i vakcinoprofilaktika
Language(s) - English
Resource type - Journals
eISSN - 2619-0494
pISSN - 2073-3046
DOI - 10.31631/2073-3046-2021-20-1-32-43
Subject(s) - reactogenicity , measles , medicine , rubella , immunogenicity , measles mumps rubella vaccine , mmr vaccine , vaccination , pediatrics , immunization , mumps vaccine , virology , immunology , antibody
Relevanc. Measles,mumpsandrubella,despitemanyyearsofvaccination,retaintheirepidemiologicalandsocialsignificanceatthepresenttime.The aim oftheworkistostudythesafetyandimmunogenicity.Ofthevaccineforthepreventionofmeasles,rubellaandmumpsVactrivir®inchildren'simmunization.Materials and methods. Thesafetyandimmunogenicityofthevaccinewasstudied in a simple multicenter blind comparative randomized clinical trial involving children aged 12 months and 6 years.Results. TheVactrivir®vaccineischaracterizedbylowreactogenicity,a high safety and immunogenicity profile and is comparable in terms of indicators to the foreign Priorix® vaccine, which has been used in the Russian Federation for specific prevention of measles, rubella and mumps since 2018.